Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Selling, general and administrative: 73.49M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Selling, general and administrative: 73.49M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- StoneX Reiterates Buy Rating on Liberty Braves (BATRA)
- Coinbase stock climbs as analysts maintain support
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
